v3.26.1
CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($)
$ in Millions
Jun. 30, 2026
Sep. 30, 2025
Current assets    
Cash and cash equivalents $ 440 $ 215
Accounts receivable, net - Note H [1] 256 242
Inventories - Note F 490 568
Other assets 106 180
Total current assets 1,292 1,205
Property, plant and equipment    
Cost 3,377 3,355
Accumulated depreciation 2,228 2,154
Net property, plant and equipment 1,149 1,201
Goodwill - Note G [2] 700 705
Intangibles, net - Note G 513 563
Operating lease assets, net - Note I 100 103
Restricted investments - Note E 285 297
Asbestos insurance receivable, net - Note L [3] 139 127
Deferred income taxes 157 157
Other assets 243 253
Total noncurrent assets 3,286 3,406
Total assets 4,578 4,611
Current liabilities    
Trade and other payables 198 189
Accrued expenses and other liabilities 208 213
Current operating lease obligations - Note I 18 21
Total current liabilities 424 423
Noncurrent liabilities    
Long-term debt - Note H 1,374 1,384
Asbestos litigation reserves - Note L 399 389
Deferred income taxes 31 31
Employee benefit obligations - Note K 88 96
Operating lease obligations - Note I 84 85
Other liabilities 308 299
Total noncurrent liabilities 2,284 2,284
Commitments and contingencies - Note I and L
Equity - Note N 1,870 1,904
Total liabilities and equity $ 4,578 $ 4,611
[1] Accounts receivable, net includes an allowance for credit losses of $4 million and $2 million at June 30, 2026 and September 30, 2025, respectively.
[2] As of both June 30, 2026 and September 30, 2025, there were accumulated impairments of $375 million, $356 million, $505 million and $90 million related to the Life Sciences, Personal Care, Specialty Additives and Intermediates reportable segments, respectively.
[3] Asbestos insurance receivable, net includes an allowance for credit losses of $2 million at both June 30, 2026 and September 30, 2025.